Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTP
Authors:
- Kamran DarabiKDKamran Darabi
- Anders H. BergABAnders H. Berg
- 1 April 2006
- journal article
- case report
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 125 (4) , 592-597
Abstract
Much of idiopathic thrombotic thrombocytopenic purpura (TTP) is attributed to the presence of an autoantibody to ADAMTS13, the metalloprotease that degrades ultralarge von Willebrand protein multimers. Most patients respond to treatment with therapeutic plasma exchange (TPE), which replaces the missing protease and removes the circulating inhibitor. However, a substantial fraction of idiopathic TTP cases (10%-20%) might not respond to TPE alone, and, therefore, interest has been gathering around the use of the novel immunosuppressive anti-B-cell antibody, rituximab. We report 2 cases of refractory TTP in which the combined use of plasma exchange and rituximab was associated with clinical resolution of active TTP, and we discuss the benefits and possible timing of combined therapy.Keywords
This publication has 8 references indexed in Scilit:
- Rituximab in patients with refractory thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2004
- Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic LeukemiaThe Journal of Immunology, 2004
- Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literatureBritish Journal of Haematology, 2004
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003
- Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemiasBritish Journal of Haematology, 2003
- Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and RituximabAnnals of Internal Medicine, 2003
- Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximabAmerican Journal of Hematology, 2002
- Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic PurpuraJournal of Biological Chemistry, 2001